Informace o publikaci

The effectiveness of treatment of benign oesophageal strictures resistant to the balloon dilation by biodegradable stents

Autoři

ČERNÁ M KÖCHER M VÁLEK Vlastimil PÁNEK Jiří ANDRAŠINA Tomáš

Rok publikování 2012
Druh Konferenční abstrakty
Citace
Popis Purpose The aim of our study is to present three-year experience in the treatment of benign oesophageal strictures resistant to the balloon dilation by biodegradable stents. Material and Methods From 2007 to 2011 we treated 22 patients (16 men, 6 women, mean age 68.2 years) by 29 biodegradable SX ELLA esophageal stent for benign oesophageal strictures resistant to the balloon dilation. Biodegradable SX ELLA esophageal stent is a self-expandable stent braided from absorbable polydioxanone monofilament. The etiology of stricture was caustic in 2 patients, actinotherapy in 3, postoperative in 7, chronic mycosis in 1 and gastroesophageal reflux disease in 9 patients. Statistical analysis was performed by Kaplan-Meier analysis. Results Stent placement was successful in 21 patients. Technical success was 96.5%. Pain was observed in 2 patients, migration in 2, fistula in one and massive arterial bleeding in one. The mean follow-up was 13.9 months (1-57 months). Primary patency rate was 83.1% (SE: 3.9%), 67.5% (SE: 5%), 58% (SE: 5.9%) a 48.4% (SE: 7.1%) at 6, 12, 24 and 36 months, respectively. Primary patency was 8.7 months, 95% CI: 3.5–13.9 months. Primary-assisted patency (additional effective balloon dilatation) was 12.4 months, 95% CI: 6.4–18.4 months. Conclusion The use of biodegradable SX ELLA esophageal stent is feasible and safe. Its use eliminates the need of removing the stent after long-term dwelling in situ as well as the risk of complications related to the removal. However, mucosal hyperplasia and restenosis are relatively frequent complications.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info